

## **Intra-Cellular Therapies to Present at the Cowen and Company 38th Annual Health Care Conference**

March 8, 2018

NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Cowen and Company 38<sup>th</sup> Annual Health Care Conference in Boston, MA. The presentation is scheduled for Tuesday, March 13, 2018 at 9:20 am ET.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at [www.intracellularterapies.com](http://www.intracellularterapies.com). Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

### **About Intra-Cellular Therapies**

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. Lumateperone, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company's PDE1 portfolio, ITI-214, is in development for the treatment of symptoms associated with Parkinson's disease.

### **CONTACT:**

Intra-Cellular Therapies, Inc.  
Juan Sanchez, M.D.  
Vice President  
Corporate Communications and Investor Relations  
646-440-9370

Burns McClellan, Inc.  
Lisa Burns  
Justin Jackson (Media)  
[jjackson@burnsmc.com](mailto:jjackson@burnsmc.com)  
212-213-0006

[Primary Logo](#)

Source: Intra-Cellular Therapies Inc.